Edition:
United States

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

8.44USD
3:59pm EST
Change (% chg)

$0.47 (+5.90%)
Prev Close
$7.97
Open
$7.93
Day's High
$8.56
Day's Low
$7.90
Volume
176,068
Avg. Vol
513,441
52-wk High
$25.11
52-wk Low
$5.91

Latest Key Developments (Source: Significant Developments)

Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement
Monday, 11 Dec 2017 05:35pm EST 

Dec 11 (Reuters) - Merck & Co Inc ::NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014.NEWLINK GENETICS-UNDER MERCK AMENDMENT, MODIFIED MERCK'S SUBLICENSE OF IP RIGHTS UNDER PHAC LICENSE AGREEMENT TO BE NON-EXCLUSIVE ON EBOLA SUDAN FIELD OF USE.NEWLINK GENETICS - AMENDMENT ALSO ADJUSTS EXPIRATION OF MERCK'S OBLIGATION TO PAY ROYALTIES TO BPS BASED ON ROYALTY TERM OF PHAC LICENSE AGREEMENT.  Full Article

NewLink Genetics reports Q3 loss per share $0.69
Thursday, 2 Nov 2017 08:00am EDT 

Nov 2 (Reuters) - NewLink Genetics Corp :Q3 loss per share $0.69.NewLink Genetics Corp - ‍Expect to end 2017 with approximately $150 million in cash and equivalents​.NewLink Genetics Corp - Qtrly ‍total operating revenues $5.5 million versus $15.3 million.Q3 earnings per share view $-0.74, revenue view $3.4 million -- Thomson Reuters I/B/E/S.  Full Article

Newlink genetics announces FDA orphan-drug designation for Indoximod
Monday, 30 Oct 2017 09:00am EDT 

Oct 30 (Reuters) - Newlink Genetics Corp :Newlink Genetics announces FDA orphan-drug designation for Indoximod.‍Indoximod was granted orphan-drug designation by U.S. FDA for treatment of patients with stage IIB-IV melanoma​.  Full Article

Newlink Genetics prices public offering of common stock
Tuesday, 3 Oct 2017 08:53pm EDT 

Oct 3 (Reuters) - Newlink Genetics Corp :Newlink Genetics prices public offering of common stock.Newlink Genetics Corp - priced underwritten public offering of 5 million shares of its common stock at a price to public of $10.25 per share.  Full Article

NewLink Genetics announces proposed public offering of common stock
Tuesday, 3 Oct 2017 04:07pm EDT 

Oct 3 (Reuters) - Newlink Genetics Corp :NewLink Genetics announces proposed public offering of common stock.NewLink Genetics Corp - ‍intends to offer and sell up to $50 million of shares of its common stock in an underwritten public offering​.NewLink Genetics - ‍intends to use net proceeds from offering to fund research, development efforts to further advance its pipeline of product candidates​.  Full Article

NewLink Genetics forecasts co will have about $100 million in cash and cash equivalents on balance sheet
Monday, 25 Sep 2017 06:43am EDT 

Sept 25 (Reuters) - NewLink Genetics Corp :NewLink Genetics - forecasts that co will have about $100 million in cash and cash equivalents on its balance sheet as of December 31, 2017 - SEC filing.  Full Article

NewLink Genetics announces clinical collaboration with AstraZeneca​
Monday, 25 Sep 2017 06:00am EDT 

Sept 25 (Reuters) - NewLink Genetics Corp :Newlink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer.NewLink Genetics Corp - ‍Phase 2 trial will be funded equally by both companies, with NewLink Genetics serving as study sponsor​.NewLink Genetics Corp - ‍announced that it has entered into a clinical collaboration agreement with AstraZeneca​.NewLink Genetics Corp - NewLink Genetics' share of aggregate expense of trial is not expected to have a material effect on its financial position​.NewLink Genetics Corp - ‍patients will also be enrolled into a smaller cohort evaluating combination of durvalumab with gemcitabine/abraxane​.  Full Article

Newlink Genetics says Millennium Management reports 5.8 pct passive stake in co
Wednesday, 13 Sep 2017 04:50pm EDT 

Sept 14 (Reuters) - Newlink Genetics Corp :Millennium Management LLC reports 5.8 percent passive stake in Newlink Genetics Corp as of September 8, 2017 - SEC filing.  Full Article

Newlink Genetics says on July 28, company announced that it has implemented "significant" restructuring program
Friday, 28 Jul 2017 09:21am EDT 

July 28 (Reuters) - NewLink Genetics Corp ::Says on July 28, 2017, company announced that it has implemented a "significant" restructuring program - sec filing.Objective of restructuring is to focus company's resources on development of indoximod and nlg802.NewLink Genetics - restructuring includes elimination of spending for programs outside of indoximod, about 50 percent reduction in headcount to about 70.  Full Article

NewLink Genetics Q2 loss per share $0.57
Friday, 28 Jul 2017 08:00am EDT 

July 28 (Reuters) - Newlink Genetics Corp ::Q2 loss per share $0.57.NewLink Genetics - ‍expect to end 2017 with approximately $75 million in cash and equivalents, which excludes any cash that may be received from financing​.NewLink Genetics Corp - qtrly ‍total operating revenues $10.4 million versus $2 million.Q2 earnings per share view $-0.73 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement

* NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014